|
Name |
cis-2-Thujen-4-ol
|
| Molecular Formula | C10H16O | |
| IUPAC Name* |
2-methyl-5-propan-2-ylbicyclo[3.1.0]hex-3-en-2-ol
|
|
| SMILES |
CC(C)C12CC1C(C=C2)(C)O
|
|
| InChI |
InChI=1S/C10H16O/c1-7(2)10-5-4-9(3,11)8(10)6-10/h4-5,7-8,11H,6H2,1-3H3
|
|
| InChIKey |
MSEVJTQZWWZGMP-UHFFFAOYSA-N
|
|
| Synonyms |
cis-2-Thujen-4-ol; 2-Thujen-4-ol; Thuja-2-ene-4-ol; 2-methyl-5-propan-2-ylbicyclo[3.1.0]hex-3-en-2-ol; SCHEMBL11519419; CHEBI:171917; DTXSID401317591; 5-Isopropyl-2-methylbicyclo[3.1.0]hex-3-en-2-ol #; 2-methyl-5-(1-methylethyl)-bicyclo[3.1.0]hex-3-en-2-ol; 2-methyl-5-(propan-2-yl)bicyclo[3.1.0]hex-3-en-2-ol; 83260-52-0; Bicyclo[3.1.0]hex-3-en-2-ol, 2-methyl-5-(1-methylethyl)-, (1.alpha.,2.alpha.,5.alpha.)-
|
|
| CAS | 83260-52-0 | |
| PubChem CID | 561870 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 152.23 | ALogp: | 2.0 |
| HBD: | 1 | HBA: | 1 |
| Rotatable Bonds: | 1 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 20.2 | Aromatic Rings: | 2 |
| Heavy Atoms: | 11 | QED Weighted: | 0.573 |
| Caco-2 Permeability: | -4.177 | MDCK Permeability: | 0.00003090 |
| Pgp-inhibitor: | 0 | Pgp-substrate: | 0.001 |
| Human Intestinal Absorption (HIA): | 0.009 | 20% Bioavailability (F20%): | 0.002 |
| 30% Bioavailability (F30%): | 0.016 |
| Blood-Brain-Barrier Penetration (BBB): | 0.989 | Plasma Protein Binding (PPB): | 62.76% |
| Volume Distribution (VD): | 1.272 | Fu: | 45.22% |
| CYP1A2-inhibitor: | 0.063 | CYP1A2-substrate: | 0.625 |
| CYP2C19-inhibitor: | 0.15 | CYP2C19-substrate: | 0.869 |
| CYP2C9-inhibitor: | 0.037 | CYP2C9-substrate: | 0.224 |
| CYP2D6-inhibitor: | 0.046 | CYP2D6-substrate: | 0.184 |
| CYP3A4-inhibitor: | 0.667 | CYP3A4-substrate: | 0.381 |
| Clearance (CL): | 7.391 | Half-life (T1/2): | 0.382 |
| hERG Blockers: | 0.007 | Human Hepatotoxicity (H-HT): | 0.059 |
| Drug-inuced Liver Injury (DILI): | 0.032 | AMES Toxicity: | 0.008 |
| Rat Oral Acute Toxicity: | 0.345 | Maximum Recommended Daily Dose: | 0.115 |
| Skin Sensitization: | 0.08 | Carcinogencity: | 0.521 |
| Eye Corrosion: | 0.006 | Eye Irritation: | 0.952 |
| Respiratory Toxicity: | 0.106 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC001145 | ![]() |
0.400 | D06GIP | ![]() |
0.184 | ||
| ENC002232 | ![]() |
0.381 | D04CSZ | ![]() |
0.184 | ||
| ENC000653 | ![]() |
0.381 | D01CKY | ![]() |
0.181 | ||
| ENC000872 | ![]() |
0.349 | D07QKN | ![]() |
0.173 | ||
| ENC002264 | ![]() |
0.349 | D0A3HB | ![]() |
0.167 | ||
| ENC005252 | ![]() |
0.319 | D05VQI | ![]() |
0.167 | ||
| ENC000360 | ![]() |
0.319 | D0P0HT | ![]() |
0.161 | ||
| ENC003268 | ![]() |
0.298 | D0H1QY | ![]() |
0.160 | ||
| ENC005117 | ![]() |
0.298 | D08PIQ | ![]() |
0.159 | ||
| ENC004312 | ![]() |
0.288 | D0CW1P | ![]() |
0.156 | ||